A landmark study published in JAMA Internal Medicine in June 2024 found that roughly 4 million Americans currently taking statins for primary prevention — meaning they have never had a heart attack or stroke — may not actually need the drugs. The study applied the American Heart Association’s newer PREVENT risk calculator and determined that the number of adults who would qualify for statin therapy drops from 45.4 million to about 28.3 million, a reduction of nearly 40 percent. For the millions of older adults managing brain health alongside cardiovascular concerns, this finding raises an urgent and practical question: should you still be taking that pill every morning? But the picture is far from simple.
While some people may be overtreated, a separate July 2025 Johns Hopkins study found that only 23 percent of the 47 percent of Americans who are eligible for statins under current guidelines have actually been prescribed them — and that closing this gap could prevent more than 39,000 deaths, nearly 100,000 non-fatal heart attacks, and up to 65,000 strokes each year. The statin debate, in other words, cuts both ways. This article breaks down what the latest research actually says, who may be overtreated, who may be undertreated, what the real side effects are, and what all of this means for people concerned about long-term brain health and dementia risk.
Table of Contents
- Why Do Studies Say Millions of Americans Are Taking Statins They Don’t Need?
- The Danger of Pulling Back Too Fast
- What the Latest Research Says About Statin Side Effects
- How to Know If Your Statin Prescription Still Makes Sense
- The Expectation Gap — Why Patients and Doctors Talk Past Each Other
- The Brain Health Connection
- What Comes Next — New Guidelines on the Horizon
- Conclusion
- Frequently Asked Questions
Why Do Studies Say Millions of Americans Are Taking Statins They Don’t Need?
The core issue comes down to how cardiovascular risk is calculated. For over a decade, doctors relied on the 2013 Pooled Cohort Equations to estimate a patient’s 10-year risk of heart attack or stroke. Those equations were widely criticized for overestimating risk, which meant more people crossed the threshold where guidelines recommended statin therapy. The AHA’s newer PREVENT equation, which removes race as a variable and incorporates kidney disease and current statin use, paints a different picture. When researchers applied it to the U.S.
population, 17 million fewer people qualified for the drugs. Consider a 62-year-old woman with mildly elevated cholesterol, no diabetes, and healthy kidneys. Under the old calculator, her estimated risk might have been high enough to trigger a statin prescription. Under PREVENT, that same woman might fall well below the treatment threshold. Multiply that scenario across primary care offices nationwide, and you begin to see how the system ended up with over 40 million Americans — one in four adults over 40 — taking statins, a market worth more than $20 billion annually. Statin use more than doubled between 2009 and 2019, driven in part by a risk calculator that was, by many accounts, too aggressive.
The Danger of Pulling Back Too Fast
However, if doctors and patients react to these findings by broadly discontinuing statins, the consequences could be severe. A follow-up analysis reported by STAT News in July 2024 estimated that adopting the new PREVENT calculator without other adjustments could lead to 107,000 additional heart attacks and strokes over a 10-year period. That is not a theoretical number — it represents real people who would suffer preventable cardiovascular events because their risk was reclassified downward. The Johns Hopkins study from July 2025 underscores this concern from a different angle.
Researchers found that full guideline-aligned statin treatment across the eligible population could prevent staggering numbers of cardiovascular events annually. Dr. Seth Martin of Johns Hopkins has been blunt about the problem: “In general, there’s been an exaggeration of the dangers of statins.” He notes that statins can reduce the risk of stroke, heart attack, and cardiovascular death by 25 percent or more. For people worried about dementia and cognitive decline, stroke prevention is particularly relevant — stroke is one of the strongest known risk factors for vascular dementia and can accelerate Alzheimer’s disease progression.
What the Latest Research Says About Statin Side Effects
One of the biggest barriers to statin adherence has been fear of side effects, from muscle pain to cognitive fog to liver damage. A major Lancet meta-analysis published in February 2026 examined 66 possible adverse effects commonly attributed to statins and found that 62 of them are unsupported by reliable scientific evidence. The only well-established side effects are muscle pain, which affects roughly 1 percent of users, and a small increase in blood sugar levels.
This matters enormously for the dementia care community. For years, anecdotal reports of “brain fog” on statins circulated widely, leading some patients and caregivers to discontinue the drugs out of fear they were worsening cognitive decline. The Lancet findings suggest that most of these concerns are driven by the nocebo effect — people expecting side effects and then experiencing them — rather than by the pharmacology of the drugs themselves. That said, the 1 percent who do experience genuine muscle pain deserve to have their symptoms taken seriously, and alternative medications or adjusted dosing should be discussed with a physician rather than ignored.
How to Know If Your Statin Prescription Still Makes Sense
The critical variable is your actual cardiovascular risk, which depends on age, sex, blood pressure, cholesterol levels, diabetes status, kidney function, and smoking history. Research from the University of Zurich, published in the Annals of Internal Medicine, offers some concrete thresholds. For men aged 70 to 75 with no history of cardiovascular symptoms, the harms of statin therapy outweigh the benefits unless their 10-year cardiovascular risk exceeds 21 percent. For women in the same age range, the threshold is 22 percent.
For younger adults aged 40 to 44, the calculus shifts: benefits outweigh harms at 14 percent risk for men and 17 percent for women. These numbers reveal an important tradeoff. Older adults face a higher baseline risk of cardiovascular events, but they also face greater potential for drug interactions, polypharmacy complications, and diminishing returns from long-term prevention. A 73-year-old woman on five other medications has a different risk-benefit profile than a 45-year-old man whose only health concern is elevated LDL cholesterol. The conversation with your doctor should be specific to your numbers, not based on general headlines about statins being “overprescribed” or “underprescribed.”.
The Expectation Gap — Why Patients and Doctors Talk Past Each Other
A separate JAMA Internal Medicine study from February 2026 uncovered another wrinkle in the statin debate: patients often expect two to three times more risk reduction than statins actually deliver before they are willing to commit to taking a daily pill. In practical terms, if statins reduce a person’s 10-year heart attack risk from 12 percent to 9 percent — a meaningful but modest absolute reduction — many patients feel that benefit is not worth the daily commitment and perceived side effect risk. This expectation gap creates a communication problem.
Doctors who focus on relative risk reduction (a 25 percent decrease sounds impressive) may leave patients feeling misled when they later learn the absolute numbers. Conversely, patients who fixate on absolute risk reduction may undervalue a drug that, across a population, prevents tens of thousands of heart attacks and strokes. For caregivers managing a loved one’s dementia alongside their cardiovascular health, this is not an abstract debate — it is a daily medication decision that requires honest, specific information rather than blanket reassurance.
The Brain Health Connection
Statins occupy a complicated place in dementia research. Some observational studies have suggested that long-term statin use may be associated with lower dementia risk, potentially through vascular protection and anti-inflammatory effects.
Others have found no significant cognitive benefit. What is clearer is the indirect connection: by reducing the risk of stroke and maintaining healthy blood flow to the brain, statins may help protect against vascular cognitive impairment, the second most common cause of dementia after Alzheimer’s disease. For someone already showing early signs of cognitive decline, a stroke could be catastrophic — and statins remain one of the most effective tools for stroke prevention in eligible patients.
What Comes Next — New Guidelines on the Horizon
New guidelines from the American College of Cardiology and the AHA, built around the PREVENT risk equations, are expected by the second quarter of 2026. These updated recommendations will likely reshape who gets prescribed statins and at what thresholds. Cardiologists including Dr.
Rita Redberg and Dr. John Abramson of Harvard have urged caution against expanding statin prescriptions to millions of people with no history of heart disease, while others argue the bigger public health failure is undertreating those who would genuinely benefit. What virtually every expert agrees on is this: patients should not stop taking statins on their own without consulting their doctor. The decision to start, continue, or stop statin therapy should be individualized, based on current risk calculators, honest conversations about benefits and side effects, and the patient’s full medical picture.
Conclusion
The statin debate in 2026 is not a simple story of overprescription or underprescription — it is both, simultaneously. An estimated 4 million Americans may be taking statins they do not need for primary prevention, while tens of millions more who could benefit from the drugs have never been prescribed them. The old risk calculators pushed too many low-risk people toward medication while the medical system simultaneously failed to reach higher-risk patients who stood to gain the most.
For families navigating dementia care, the takeaway is specific and actionable: do not stop or start a statin based on headlines. Ask your doctor to run your numbers through the PREVENT calculator, discuss the absolute (not just relative) risk reduction for your situation, and weigh that against the now-clarified side effect profile. With new ACC/AHA guidelines expected in 2026, this is the right time to have that conversation — armed with better data than we have ever had before.
Frequently Asked Questions
Should I stop taking my statin based on the new PREVENT calculator findings?
No. Cardiologists universally caution against stopping statins without consulting your doctor. The PREVENT calculator changes who might be newly recommended for statins, but your individual risk profile, medication history, and health conditions all factor into whether continuing makes sense for you.
Do statins cause memory loss or brain fog?
The February 2026 Lancet meta-analysis found that 62 of 66 commonly reported statin side effects, including cognitive complaints, are unsupported by reliable evidence. While some individuals report subjective cognitive changes, large-scale data does not support a causal link between statins and memory loss.
Can statins help prevent dementia?
The evidence is mixed but leaning cautiously positive. Statins reduce stroke risk by 25 percent or more, and stroke is a major risk factor for vascular dementia. Some observational studies suggest a protective effect against cognitive decline, though no randomized trial has proven statins prevent Alzheimer’s disease specifically.
What are the real, proven side effects of statins?
According to the 2026 Lancet meta-analysis, the only well-established side effects are muscle pain (affecting about 1 percent of users) and a small increase in blood sugar levels. The vast majority of other reported side effects lack strong scientific support.
How do I know if my cardiovascular risk is high enough to justify a statin?
Ask your doctor to calculate your 10-year cardiovascular risk using the PREVENT equation. Research suggests that for adults aged 70 to 75, benefits outweigh harms when 10-year risk exceeds roughly 21 to 22 percent. For younger adults aged 40 to 44, the threshold is lower — around 14 to 17 percent depending on sex.
When will the new statin guidelines be released?
Updated guidelines from the American College of Cardiology and the AHA, based on the PREVENT risk equations, are expected by the second quarter of 2026.
